Paxlovid antiviral therapy reduces risk of long COVID - Video
|
Overview
Pfizer Inc.'s blockbuster Paxlovid antiviral that lowers rates of illness and death in people infected with the coronavirus also cuts the risk of some symptoms of disabling long Covid, a study found.
Taking the oral medication within five days of testing positive for a SARS-CoV-2 infection was linked to a 26% lower risk of lingering post-viral complications, researchers with the Veterans Affairs St. Louis Health Care System said in the study. That equates to 2.3 fewer cases of long Covid within three months of infection for every 100 patients treated, according to the findings released Saturday on the medRxiv server ahead of publication in a peer-reviewed journal.
Speakers
Roshni Dhar, a Mass com graduate with a soft corner for health happenings, joined Medical Dialogues as a news anchor in 2021. Inspired by her mother who is a gynaecologist, she likes to keep herself and the world updated on the occurring in the medical field. She covers various aspects of health news for MDTV at Medical Dialogues. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
